R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Director of US Medical Affairs - Non-Small Cell Lung Cancer

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • An advanced clinical or scientific degree such as PharmD, PhD, MD, DO, or equivalent is required.
  • 10+ years of relevant experience in biotechnology or pharmaceutical Medical Affairs and/or clinical oncology practice, including substantive hands-on Medical Affairs experience.
  • Strong scientific background in lung cancer, with direct NSCLC experience and an understanding of biomarker-driven treatment and the US treatment landscape.
  • Demonstrated ability to analyze, synthesize, and communicate complex clinical evidence with scientific accuracy and appropriate balance.
  • Hands-on experience across core Medical Affairs activities, including medical planning, external expert engagement, field medical partnership, medical communications, evidence generation, congresses, advisory boards, and training.
  • Demonstrated ability to collaborate and influence across functions, manage multiple projects and stakeholders, and deliver against agreed priorities.
  • Excellent written, verbal, and presentation skills, with sound judgment and a commitment to ethical scientific exchange.
  • Ability to travel approximately 30–40% for external expert engagements, medical congresses, and internal meetings, including visits to Redwood City headquarters.

Responsibilities

  • Contribute to the US NSCLC medical strategy and annual portfolio plan; lead assigned tactics with clear objectives, timelines, budgets, and measures of impact.
  • Conduct evidence and practice-gap assessments, incorporating US treatment patterns, stakeholder needs, competitive developments, and field insights to refine medical priorities.
  • Support launch readiness, launch execution, and lifecycle planning across NSCLC assets in alignment with US and Global Medical Affairs strategies.
  • Lead or support scientific engagement with US external experts through advisory boards, investigator interactions, congress activities, and peer-to-peer scientific exchange.
  • Partner with US Field Medical on scientific priorities, insight-generation plans, training, and resources that support high-quality scientific exchange.
  • Synthesize insights from external experts, field teams, advisory boards, and congresses; communicate implications and recommend actions to internal stakeholders.
  • Serve as an NSCLC medical content expert on cross-functional teams, providing scientifically balanced input into US strategic discussions and decisions.
  • Partner with HEOR/RWE, Clinical Development, and Biomarker/Companion Diagnostics teams on evidence-generation priorities, including patient identification, molecular testing, treatment sequencing, safety management, and patient outcomes.
  • Collaborate with Clinical Development, Clinical Operations, and Field Medical to support protocol review, site and investigator engagement, and appropriate trial awareness and enrollment activities.
  • Contribute to publication, congress, medical communications, and data-disclosure plans; develop or review scientific presentations, abstracts, manuscripts, educational content, and medical information response documents.
  • Provide medical leadership for assigned US congress activities, scientific symposia, advisory boards, and internal education, ensuring scientific accuracy and consistency.
  • Partner with Patient Advocacy to incorporate patient and caregiver perspectives, and with Grants teams to identify priorities for independent medical education.
  • Collaborate with Safety and Clinical teams on education and scientific exchange concerning adverse-event recognition and management in NSCLC.
  • Manage assigned vendors and resources, track execution and outcomes, and conduct all activities in accordance with applicable requirements, company policies, and Revolution Medicines Core Values.

Desired Qualifications

  • Established relationships with US thoracic oncology experts, investigators, and multidisciplinary care stakeholders in academic and community settings.
  • Experience supporting US oncology launch readiness, launch execution, or post-launch medical strategy.
  • Experience in precision oncology, RAS biology, targeted therapies, molecular testing, and companion diagnostics.
  • Experience supporting clinical-trial strategy or execution, including protocol review, site engagement, enrollment support, and clinical data interpretation.
  • Experience contributing to guideline or compendium submissions, such as NCCN, and collaborating with Global Medical Affairs on integrated medical and evidence-generation plans.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs